Menu

Pharma News

Meeting V13F14

Bio-Thera and Gedeon Richter partner to commercialize Stelara biosimilar BAT2206

Home/Pharma News | Posted 05/11/2024

In October 2024, China based Bio-Thera Solutions (Bio-Thera) and Hungary’s Gedeon Richter announced they have reached an exclusive commercialization and license agreement for BAT2206, a biosimilar candidate to Johnson & Johnson’s Stelara (ustekinumab).

AA010968

Advances for Biocon Biologics’ Stelara and Eylea biosimilars

Home/Pharma News | Posted 24/09/2024

Biocon Biologics (Biocon) settled patent disputes with Janssen to commercialize Bmab 1200, a biosimilar of Stelara (ustekinumab), in several markets, including Europe and Canada. Additionally, Biocon received UK marketing authorization for Yesafili, its biosimilar of Eylea (aflibercept).

16704526_l

China’s Hasten Biopharma acquires 14 products from Celltrion

Home/Pharma News | Posted 10/09/2024

In July 2024, it was announced that China’s Hasten Biopharmaceutical has acquired the asset rights of 14 branded products across Pan-Asia countries and regions from Korea’s Celltrion.

Application V15a16

Coherus sells adalimumab biosimilar Yusimry to HKF for US$40 million amid oncology focus

Home/Pharma News | Posted 16/07/2024

On 27 June 2024, Coherus BioSciences announced that is has divested Yusimry (aflibercept-jbvf), an adalimumab biosimilar to AbbVie’s rheumatoid arthritis therapy Humira, to Hong Kong King-Friend Industrial (HKF) in a US$40 million deal.

Diabetes V14K06

Biocon and Biomm forge alliance to bring semaglutide diabetes treatment to Brazil

Home/Pharma News | Posted 12/06/2024

By mid-April 2024, India-based Biocon Biologics signed an exclusive licensing and supply agreement that will allow Brazil’s Biomm SA to commercialise semaglutide, which is used to control type-2 diabetes in adults and has been repurposed for obesity management.

Shaking hands V13D29

Klinge–MS Pharma and Teva–mAbxience biosimilars licence agreements

Home/Pharma News | Posted 05/06/2024

In May 2024, Klinge Biopharma announced an exclusive licensing and supply agreement with MS Pharma for FYB203 commercialization in the Middle East and North Africa (MENA) region. Previously, in April 2024, mAbxience and Teva Pharmaceuticals signed a strategic licensing agreement for a biosimilar candidate for oncology treatment.

Turkey 2016 COVER V16E31DG

Celltrion wins Peruvian public tenders for biosimilar infliximab and trastuzumab

Home/Pharma News | Posted 28/05/2024

In early May 2024, Celltrion reported that two of its biosimilar products, infliximab and trastuzumab, won the public tender in Peru, further expanding their prescription availability in Peru and solidifying their position in the broader Latin American pharmaceutical market.

02 AA010638

Bio-Thera and SteinCares sign agreement to market two biosimilars in LATAM

Home/Pharma News | Posted 14/05/2024

Bio-Thera Solutions (Bio-Thera) announced in March 2024 a licensing agreement with SteinCares to market two biosimilars in Brazil and the rest of the region.

Blue eye with data points

Formycon launches biosimilar ranibizumab Ravegza in Saudi, Gedeon Richter invests

Home/Pharma News | Posted 07/05/2024

In March 2024, Formycon and MS Pharma announced that their FYB201/ranibizumab Ravegza, a biosimilar to Lucentis, has received marketing authorization from the Saudi Food and Drug Authority.

Fabry Agalsidase beta V17J06

mAbxience and Biosidus sign an agreement to manufacture Agalsidase Beta

Home/Pharma News | Posted 09/04/2024

mAbxience announced in February 2024 a pivotal agreement with Biosidus to manufacture Agalsidase Beta. This joint effort is expected to have a significant impact on the lives of patients affected by Fabry disease.

Acquisition Fall Off V13F07

Biosimilars lawsuits and settlement updates for Regeneron and Alvotech

Home/Pharma News | Posted 22/03/2024

In January 2024, Regeneron filed a lawsuit against Amgen in the federal court in Los Angeles, alleging Amgen's proposed biosimilar of Regeneron's Eylea (aflibercept) violates patent rights. Additionally, in February 2024, Iceland-based Alvotech announced the anticipated global market entry dates for AVT04, a ustekinumab biosimilar to Stelara, following its settlement with Johnson & Johnson.

Cancer Cell V13I20

The journey of Pectuna pertuzumab follow-on biological in Iran

Home/Pharma News | Posted 29/02/2024

Pertuzumab is a monoclonal antibody (mAb) that inhibits the dimerization of human epidermal growth factor receptor 2 (HER2) with other HER receptors, which prevents them from signalling in ways that promote cell growth and proliferation. It is a pivotal therapeutic in oncology, targeting the overexpressed HER2 protein, particularly in breast cancer [1].

Age-related macular degeneration V15b19

Sandoz US acquisition of ranibizumab biosimilar from Coherus

Home/Pharma News | Posted 09/02/2024

On 22 January 2024, it was announced that in the US, Sandoz will acquire ranibizumab biosimilar Cimerli (ranibizumab) from Coherus BioSciences.

Remicade V13F28

Fiocruz and Pfizer sign agreement for generic of Xeljanz

Home/Pharma News | Posted 30/01/2024

Farmanguinhos/Fiocruz, the Institute of Drug Technology in Brazil, has signed a technology transfer agreement with Pfizer Brazil for the manufacturing of tofacitinib citrate, a generic counterpart to Xeljanz.

EU Flag V12K23

Biocon to commercialize biosimilars in 31 European countries

Home/Pharma News | Posted 23/01/2024

Biocon Biologics has successfully integrated Viatris’ biosimilars business in 31 European countries, it was announced in late November 2023.

Law V13C29

J&J lawsuits settled over ustekinumab biosimilars

Home/Pharma News | Posted 24/07/2023

Johnson & Johnson (J&J), the maker of Stelara (ustekinumab), settled two lawsuits, one against Amgen, and the other against Alvotech and Teva Pharmaceuticals. Both lawsuits were over proposed ustekinumab biosimilars for the treatment of autoimmune conditions. These were settled in May and June 2023, respectively.

10 AA008993

Genfar: Eurofarma's new generic brand in Latin America

Home/Pharma News | Posted 12/12/2023

Eurofarma announced on 29 September 2023 that it completed the acquisition of Laboratorios Genfar. Genfar is a generic drug company owned by the French company Sanofi, with offices in Colombia, Ecuador, and Peru.

Multiple Sclerosis V14A24

Phase III trial results of CinnaGen’s ocrelizumab similar biotherapeutic product

Home/Pharma News | Posted 28/11/2023

Ocrelizumab is a therapeutic monoclonal antibody (mAb) that represents a different scientific approach to treating multiple sclerosis (MS). It is a humanized anti-CD20 mAb that targets CD20 marker on B lymphocytes, a typo of immune cell that plays a key role in the disease and serves as an immunosuppressive drug. Ocrelizumab binds selectively to CD20, which is expressed on the membrane of B cells. When ocrelizumab binds to CD20 on B cells, these cells are eliminated by antibody-dependent cell-mediated cytotoxicity and, to a lesser extent, complement-dependent cytotoxicity.

63 MD002127

Insulin biosimilars: new CRL for Biocon, new deal for Meitheal/Tonghua Dongbao

Home/Pharma News | Posted 21/11/2023

In a dynamic landscape of pharmaceutical developments, Biocon Biologics (Biocon) faces a regulatory hurdle with a complete response letter from the US Food and Drug Administration (FDA), while Meitheal Pharmaceuticals expands its reach through a strategic licensing agreement with Tonghua Dongbao Pharmaceutical.

Shaking hands V13D29

Abbott and mAbxience partnership for biosimilars in emerging markets

Home/Pharma News | Posted 14/11/2023

Abbott and mAbxience announced on 20 September 2023 that they had entered into a strategic partnership to commercialize several biosimilars in Latin America and other emerging markets.